TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
PolyPeptide Group AG ( (CH:PPGN) ) has shared an update.
PolyPeptide Group AG reported significant improvements in profitability and cash flow for 2024, with a revenue increase of 5.1% compared to 2023. The company is poised for strong growth, driven by operational performance and capacity expansion projects in Belgium, France, and Sweden. For 2025, PolyPeptide forecasts accelerated revenue growth of 10% to 20%, supported by new commercial production in Belgium, and plans to continue increasing its EBITDA margin. The nomination of Joanna LeCouilliard to the Board of Directors is expected to bring valuable expertise in finance and healthcare management.
More about PolyPeptide Group AG
PolyPeptide Group AG is a specialized global contract development and manufacturing organization (CDMO) focusing on peptide-based active pharmaceutical ingredients. The company serves various therapeutic areas with a strong emphasis on meeting increasing customer demand through its global production network.
YTD Price Performance: -30.99%
Average Trading Volume: 37,396
Technical Sentiment Consensus Rating: Buy
Current Market Cap: CHF647.4M
See more data about PPGN stock on TipRanks’ Stock Analysis page.